Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Local Chemoradiation Therapy +/- Surgery Versus Systemic Therapy for Oligometastatic Esophageal or Gastric Cancer
NCT03161522Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2018
- Primary completion
- Dec 2026
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fluorouracil and capecitabine in esophageal cancer and gastric cancer (GC) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Overall Survival at 6 years. Started Feb 2018; status: recruiting.
02
Drugs
fluorouracilcapecitabine
03
Conditions
esophageal cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT03161522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03161522.